APA (7th ed.) Citation

Rayson, D., Gandhi, S., Joy, A. A., Brezden-Masley, C., Gelmon, K. A., Sehdev, S., . . . Chia, S. (2023). Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891–9895”. MDPI AG.

Chicago Style (17th ed.) Citation

Rayson, Daniel, Sonal Gandhi, Anil A. Joy, Christine Brezden-Masley, Karen A. Gelmon, Sandeep Sehdev, David Cescon, and Stephen Chia. Reply to Trudeau, M.; Fraser, B. The CADTH PCODR Expert Review Committee Process Explained. Comment on “Rayson Et Al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891–9895”. MDPI AG, 2023.

MLA (9th ed.) Citation

Rayson, Daniel, et al. Reply to Trudeau, M.; Fraser, B. The CADTH PCODR Expert Review Committee Process Explained. Comment on “Rayson Et Al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891–9895”. MDPI AG, 2023.